AGT | Jotup

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on:

수요일, 5월 8, 2024

Sickle cell disease, T1D, SHR, Cell, CRISPR, Partnership, CD19, CRISPR Therapeutics, Biomarker, Autoimmunity, SCD, LNP, Lupus, Kingdom, Porphobilinogen, ADC, Eye, ANGPTL3, RAAS, PBG, Therapy, Lymphoid leukemia, Vertex Pharmaceuticals, Type 1 diabetes, Pain, Cas9, AHP, Diabetes, Research, ALA, BP, CD70, AGT, Clinical trial, Government, G&A, TDT, Sale, CRSP, ALAS1, European, Disease, Patient, Liver, Gene, Society, Stem cell, Cardiovascular disease, SLE, Pharmaceutical industry

CASGEVY is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals established in 2015.

Key Points:

CASGEVY is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals established in 2015.
CRISPR Therapeutics has two next-generation approaches with the potential to significantly expand the addressable population with SCD and TDT.
G&A Expenses: General and administrative expenses were $18.0 million for the first quarter of 2024, compared to $22.4 million for the first quarter of 2023.
Collaboration Expense: Collaboration expense, net, was $47.0 million for the first quarter of 2024, compared to $42.2 million for the first quarter of 2023.

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Retrieved on:

수요일, 5월 8, 2024

Pain, CRSP, Patient, SHR, Cas9, Cell, CRISPR, ALAS1, LNP, AHP, Gene editing, Angiotensin, Paratriathlon, RNA, IOP, ALA, Disease, Porphobilinogen, Liver, CRISPR Therapeutics, Gene, Eye, Society, Trabecular meshwork, MYOC, RAAS, Cardiovascular disease, BP, AGT, Biomarker, PBG, Therapy, Glaucoma

In addition, CRISPR Therapeutics announced the expansion of its in vivo pipeline with two new programs.

Key Points:

In addition, CRISPR Therapeutics announced the expansion of its in vivo pipeline with two new programs.
“The expansion of our in vivo pipeline speaks to the scalability of the platform and the exceptional translation capabilities of our team.
The addition of two more programs, CTX340 and CTX450, utilizing this LNP delivery technology demonstrates the modularity and scalability of the platform.
In today’s presentation, the Company presented data demonstrating efficient and specific delivery to TM cells in mouse, non-human primate, and ex vivo human eyes.

Canadian innovation taking plant-protein nutrition to new heights

Retrieved on:

월요일, 4월 15, 2024

Dynamics, Meat, Wine, Investment, Food, The Honourable, Food industry, AGT Food and Ingredients, Apex, Economic development, Athlete, AGT, Crush

This work also included early-stage development of a super high-protein base material, which contains 64 per cent more protein than cooked ground beef and uses a blend of Canadian proteins including pea, fava and canola.

Key Points:

This work also included early-stage development of a super high-protein base material, which contains 64 per cent more protein than cooked ground beef and uses a blend of Canadian proteins including pea, fava and canola.
A total of $6.3 million has been committed to the project, with Protein Industries Canada investing $2.8 million and the partners together investing the remainder.
This project represents the kind of innovation needed to advance the alternative protein industry in Canada.
Projects such as these add value to, and create new markets for, Canadian crops, generating local jobs and supporting new economic development in locations across Canada.

Akima Secures $750M Contract to Bolster U.S. Air Force IT Modernization Initiatives

Retrieved on:

화요일, 4월 23, 2024

Air force, Partnership, Springfield–Beckley Municipal Airport, Federation, COMET, USAF, Communication, IDIQ, AGT, VTC

The award has a 10-year period of performance and a total contract value of $750 million.

Key Points:

The award has a 10-year period of performance and a total contract value of $750 million.
"We're thrilled to announce our latest project in partnership with the U.S. Air Force.
"By strategically modernizing the Air Force's IT efforts, we'll aid the USAF in doing what it does best: accomplishing the impossible each and every day."
These services will be delivered at Wright-Patterson Air Force Base, Ohio and Springfield Air National Guard Base in Springfield, Ohio; and are scheduled for completion by February 2034.

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Retrieved on:

수요일, 3월 27, 2024

Research, Dicarboxylic acid, AAV, Enzyme, Development, Gene editing, CAST, Cardiovascular disease, Haemophilia, Vivisection, Patient, Primate, RNA, DNA, Wave 1, Sale, Metagenomics, G&A, IPO, Ultra, Doctor of Philosophy, Protein, MBA, Genome, SMART, Factor VIII, CRISPR, Amyloidosis, MGX, AGT, Liver, LNP, Ionis, PAM, Vaccine

EMERYVILLE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates.

Key Points:

The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses.
In addition, cash used to fund our operations was $91.4 million for the year ended December 31, 2023.
R&D Expenses: Research and development (R&D) expenses were $94.4 million for the full year ended December 31, 2023.
G&A Expenses: General and administrative (G&A) expenses were $28.8 million for the full year ended December 31, 2023.

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on:

일요일, 4월 7, 2024

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points:

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
“Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Retrieved on:

수요일, 3월 20, 2024

The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital.

Key Points:

The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital.
A replay of the call will be available two hours after the call and archived on the same webpage for six months.
A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events .
An archived webcast will be available on the Company’s website approximately two hours after the event.

Juniper Research Exposes the billion-dollar drain of Artificial Inflated Traffic (AIT) and SMS Trashing

Retrieved on:

화요일, 3월 26, 2024

Research, Communication, OTT, AI, SMS, AIT, Fraud, AGT, Mobile phone

HONG KONG, March 26, 2024 /PRNewswire/ -- Juniper Research has unveiled a critical whitepaper detailing the pervasive and insidious issue of Artificially Inflated Traffic (AIT) and SMS Trashing within the business messaging sector. The comprehensive study was conducted in collaboration with VOX Solutions, with the aim to cast light on fraudulent activities that have led to increased operational costs for enterprises by charging for non-existent SMS traffic.

Key Points:

Juniper Research and VOX Solutions have partnered to create a whitepaper which discusses the impact of Artificial Inflated Traffic and SMS This study provides crucial insights into the fraudulent practices threatening the integrity of business messaging.
HONG KONG, March 26, 2024 /PRNewswire/ -- Juniper Research has unveiled a critical whitepaper detailing the pervasive and insidious issue of Artificially Inflated Traffic (AIT) and SMS Trashing within the business messaging sector.
This new research reveals that in 2023, known AIT accounted for 18% of all international A2P SMS traffic, costing enterprises, including those of notable figures like Elon Musk, upwards of $60 million annually.
To discover more about the intricate dynamics of SMS fraud and the strategies to mitigate its impact, access the full whitepaper by Juniper Research: https://voxsolutions.co/the-impact-of-ait-sms-trashing-on-the-market-jun...

Juniper Research Exposes the billion-dollar drain of Artificial Inflated Traffic (AIT) and SMS Trashing

Retrieved on:

화요일, 3월 26, 2024

Research, Communication, OTT, AI, SMS, AIT, Fraud, AGT, Mobile phone

HONG KONG, March 26, 2024 /PRNewswire/ -- Juniper Research has unveiled a critical whitepaper detailing the pervasive and insidious issue of Artificially Inflated Traffic (AIT) and SMS Trashing within the business messaging sector. The comprehensive study was conducted in collaboration with VOX Solutions, with the aim to cast light on fraudulent activities that have led to increased operational costs for enterprises by charging for non-existent SMS traffic.

Key Points:

Juniper Research and VOX Solutions have partnered to create a whitepaper which discusses the impact of Artificial Inflated Traffic and SMS This study provides crucial insights into the fraudulent practices threatening the integrity of business messaging.
HONG KONG, March 26, 2024 /PRNewswire/ -- Juniper Research has unveiled a critical whitepaper detailing the pervasive and insidious issue of Artificially Inflated Traffic (AIT) and SMS Trashing within the business messaging sector.
This new research reveals that in 2023, known AIT accounted for 18% of all international A2P SMS traffic, costing enterprises, including those of notable figures like Elon Musk, upwards of $60 million annually.
To discover more about the intricate dynamics of SMS fraud and the strategies to mitigate its impact, access the full whitepaper by Juniper Research: https://voxsolutions.co/the-impact-of-ait-sms-trashing-on-the-market-jun...

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Retrieved on:

화요일, 3월 5, 2024

Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.

Key Points:

Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
“We are thrilled that a single dose of zilebesiran achieved clinically significant, additional reductions in systolic blood pressure when administered to patients who are not adequately controlled with commonly prescribed antihypertensives,” said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam.
“These KARDIA-2 results, showing durable additional levels of blood pressure reduction on top of what is achieved by standard of care first-line antihypertensives with an encouraging safety profile, reinforce our confidence in zilebesiran’s differentiated profile.
The primary endpoint is the change from baseline in mean SBP at Month 3, assessed by 24-hour ABPM.